La chaîne d'options affiche les données clés des options sur actions de Kairos Pharma à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Kairos Pharma..

Kairos Pharma (AMEX:KAPA) Stock, Chaîne d'Options

KAIROS PHARMA LTD

Kairos Pharma

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Kairos Pharma Ltd

KAPA GOLD INC by KAPA GOLD INC.

Press Releases

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

News

Tech Momentum Surges as IPA, HIT, SNYR, PNPN.V, KAPA and Others Drive Investor Awareness – More Stocks Inside

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

AMZN

COST

KAPA

PLRZ

PNPNF

SNYR

TSXV:PNPN

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

Aptevo Therapeutics

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

enGene Holdings

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Lunai Bioworks

Lisata Therapeutics

Moleculin Biotech

MetaVia

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

Nanoviricides

Passage Bio

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Propanc Biopharma

Rallybio

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Synlogic

Tharimmune

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

Comments

Kairos Pharma

Kairos Pharma (KAPA) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL